Login to Your Account

Pharma: Clinic Roundup

Tuesday, September 3, 2013

Teva Pharmaceutical Industries Ltd., of Jerusalem, said its final Phase III study of armodafinil (Nuvigil) as adjunct therapy in adults with major depression associated with bipolar I disorder failed to achieve the primary endpoint of determining whether armodafinil (150 mg per day) is more effective than placebo as adjunct therapy to mood stabilizers and/or atypical antipsychotics.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription